INO logo

Inovio Pharmaceuticals (INO) Selling, General & Administrative Expenses

Annual SGA

$47.58 M
-$42.60 M-47.24%

December 31, 2023


Summary


Performance

INO SGA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherINOexpensesmetrics:

Quarterly SGA

$8.61 M
-$1.59 M-15.61%

September 30, 2024


Summary


Performance

INO Quarterly SGA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherINOexpensesmetrics:

TTM SGA

-$6.67 B
-$112.88 M-1.72%

September 30, 2024


Summary


Performance

INO TTM SGA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherINOexpensesmetrics:

Selling, General & Administrative Expenses Formula

SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development

INO Selling, General & Administrative Expenses Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-47.2%-15.9%-10000.0%
3 y3 years+27.7%-82.2%-7383.6%
5 y5 years+62.3%-82.2%-7383.6%

INO Selling, General & Administrative Expenses Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-47.2%at low-82.2%at low-54.6%at low
5 y5-year-47.2%+74.9%-82.2%+15.7%-140.8%at low
alltimeall time-47.2%+1200.7%-82.2%+1956.8%<-9999.0%at low

Inovio Pharmaceuticals Selling, General & Administrative Expenses History

DateAnnualQuarterlyTTM
Sep 2024
-
$8.61 M(-15.6%)
$39.64 M(-3.2%)
Jun 2024
-
$10.21 M(-3.4%)
$40.95 M(-7.5%)
Mar 2024
-
$10.57 M(+3.2%)
$44.26 M(-7.0%)
Dec 2023
$47.58 M(-47.2%)
$10.24 M(+3.2%)
$47.58 M(-7.2%)
Sep 2023
-
$9.93 M(-26.6%)
$51.29 M(-3.6%)
Jun 2023
-
$13.52 M(-2.6%)
$53.19 M(-39.6%)
Mar 2023
-
$13.89 M(-0.4%)
$88.12 M(-2.3%)
Dec 2022
$90.19 M(+67.8%)
$13.95 M(+18.0%)
$90.19 M(-0.1%)
Sep 2022
-
$11.82 M(-75.6%)
$90.28 M(-1.5%)
Jun 2022
-
$48.46 M(+203.7%)
$91.62 M(+64.1%)
Mar 2022
-
$15.95 M(+13.6%)
$55.82 M(+3.9%)
Dec 2021
$53.75 M(+44.3%)
$14.05 M(+6.8%)
$53.75 M(+11.2%)
Sep 2021
-
$13.16 M(+3.9%)
$48.32 M(+6.7%)
Jun 2021
-
$12.67 M(-8.8%)
$45.28 M(+3.7%)
Mar 2021
-
$13.88 M(+61.1%)
$43.68 M(+17.3%)
Dec 2020
$37.25 M(+36.9%)
$8.62 M(-14.8%)
$37.25 M(-0.2%)
Sep 2020
-
$10.11 M(-8.7%)
$37.33 M(+13.5%)
Jun 2020
-
$11.07 M(+48.6%)
$32.90 M(+18.9%)
Mar 2020
-
$7.45 M(-14.4%)
$27.68 M(+1.7%)
Dec 2019
$27.20 M(-7.2%)
$8.70 M(+53.1%)
$27.20 M(+12.7%)
Sep 2019
-
$5.68 M(-2.9%)
$24.14 M(-4.4%)
Jun 2019
-
$5.85 M(-16.1%)
$25.25 M(-5.0%)
Mar 2019
-
$6.97 M(+23.8%)
$26.59 M(-9.3%)
Dec 2018
$29.32 M(+3.6%)
$5.64 M(-17.0%)
$29.32 M(-7.6%)
Sep 2018
-
$6.79 M(-5.5%)
$31.71 M(+1.5%)
Jun 2018
-
$7.19 M(-25.9%)
$31.24 M(+3.4%)
Mar 2018
-
$9.70 M(+20.7%)
$30.22 M(+6.8%)
Dec 2017
$28.29 M(+18.4%)
$8.03 M(+27.1%)
$28.29 M(+3.9%)
Sep 2017
-
$6.32 M(+2.4%)
$27.22 M(+2.1%)
Jun 2017
-
$6.17 M(-20.6%)
$26.66 M(+1.4%)
Mar 2017
-
$7.77 M(+11.5%)
$26.29 M(+10.0%)
Dec 2016
$23.89 M(+32.3%)
$6.97 M(+21.0%)
$23.89 M(+9.7%)
Sep 2016
-
$5.76 M(-0.8%)
$21.79 M(+6.8%)
Jun 2016
-
$5.80 M(+8.0%)
$20.41 M(+5.6%)
Mar 2016
-
$5.37 M(+10.5%)
$19.33 M(+7.0%)
Dec 2015
$18.06 M(+13.9%)
$4.86 M(+11.0%)
$18.06 M(+3.6%)
Sep 2015
-
$4.38 M(-7.2%)
$17.43 M(+7.6%)
Jun 2015
-
$4.72 M(+14.9%)
$16.20 M(+2.3%)
Mar 2015
-
$4.11 M(-2.8%)
$15.83 M(-0.2%)
Dec 2014
$15.86 M(+16.2%)
$4.22 M(+34.0%)
$15.86 M(-0.7%)
Sep 2014
-
$3.15 M(-27.5%)
$15.97 M(-0.8%)
Jun 2014
-
$4.35 M(+5.2%)
$16.10 M(+8.8%)
Mar 2014
-
$4.13 M(-4.8%)
$14.80 M(+8.5%)
Dec 2013
$13.64 M(+26.6%)
$4.34 M(+32.2%)
$13.64 M(+11.6%)
Sep 2013
-
$3.28 M(+7.8%)
$12.22 M(+5.2%)
Jun 2013
-
$3.05 M(+2.4%)
$11.61 M(+3.1%)
Mar 2013
-
$2.97 M(+1.9%)
$11.26 M(+4.5%)
Dec 2012
$10.78 M(-10.1%)
$2.92 M(+9.1%)
$10.78 M(-3.0%)
Sep 2012
-
$2.67 M(-0.8%)
$11.11 M(+3.3%)
Jun 2012
-
$2.70 M(+8.4%)
$10.76 M(-3.5%)
Mar 2012
-
$2.49 M(-23.5%)
$11.16 M(-6.9%)
Dec 2011
$11.99 M
$3.25 M(+40.1%)
$11.99 M(+0.9%)
DateAnnualQuarterlyTTM
Sep 2011
-
$2.32 M(-24.9%)
$11.88 M(-4.5%)
Jun 2011
-
$3.09 M(-6.8%)
$12.44 M(+0.5%)
Mar 2011
-
$3.32 M(+5.4%)
$12.38 M(+2.2%)
Dec 2010
$12.11 M(-11.4%)
$3.15 M(+9.2%)
$12.11 M(+5.0%)
Sep 2010
-
$2.88 M(-4.8%)
$11.53 M(-7.6%)
Jun 2010
-
$3.03 M(-0.7%)
$12.48 M(-9.3%)
Mar 2010
-
$3.05 M(+18.6%)
$13.75 M(+0.6%)
Dec 2009
$13.67 M(+36.6%)
$2.57 M(-32.9%)
$13.67 M(-0.1%)
Sep 2009
-
$3.83 M(-10.9%)
$13.69 M(+16.1%)
Jun 2009
-
$4.30 M(+45.0%)
$11.78 M(+11.5%)
Mar 2009
-
$2.97 M(+14.6%)
$10.57 M(+5.6%)
Dec 2008
$10.01 M(-9.7%)
$2.59 M(+34.2%)
$10.01 M(-6.3%)
Sep 2008
-
$1.93 M(-37.5%)
$10.68 M(-10.5%)
Jun 2008
-
$3.09 M(+28.5%)
$11.93 M(+6.6%)
Mar 2008
-
$2.40 M(-26.5%)
$11.19 M(+1.5%)
Dec 2007
$11.08 M(+33.4%)
$3.27 M(+2.8%)
$11.02 M(+4.5%)
Sep 2007
-
$3.18 M(+35.5%)
$10.55 M(+14.1%)
Jun 2007
-
$2.34 M(+4.9%)
$9.24 M(+5.9%)
Mar 2007
-
$2.23 M(-20.0%)
$8.73 M(+5.1%)
Dec 2006
$8.30 M(+34.2%)
$2.79 M(+49.3%)
$8.30 M(+12.6%)
Sep 2006
-
$1.87 M(+2.4%)
$7.38 M(+8.6%)
Jun 2006
-
$1.83 M(+0.7%)
$6.80 M(+4.1%)
Mar 2006
-
$1.81 M(-2.7%)
$6.53 M(+5.5%)
Dec 2005
$6.19 M(+1.0%)
$1.87 M(+44.8%)
$6.19 M(+0.4%)
Sep 2005
-
$1.29 M(-17.5%)
$6.17 M(-5.0%)
Jun 2005
-
$1.56 M(+6.0%)
$6.49 M(-0.3%)
Mar 2005
-
$1.47 M(-20.1%)
$6.50 M(+6.1%)
Dec 2004
$6.13 M(+34.2%)
$1.84 M(+14.5%)
$6.13 M(+10.8%)
Sep 2004
-
$1.61 M(+2.0%)
$5.53 M(+10.7%)
Jun 2004
-
$1.58 M(+43.9%)
$5.00 M(+13.6%)
Mar 2004
-
$1.10 M(-12.0%)
$4.40 M(-3.6%)
Dec 2003
$4.57 M(+24.8%)
$1.25 M(+15.9%)
$4.57 M(+8.1%)
Sep 2003
-
$1.08 M(+9.9%)
$4.22 M(+3.2%)
Jun 2003
-
$979.60 K(-22.5%)
$4.09 M(+1.2%)
Mar 2003
-
$1.26 M(+39.8%)
$4.04 M(+10.5%)
Dec 2002
$3.66 M(-7.9%)
$903.60 K(-4.5%)
$3.66 M(+32.8%)
Sep 2002
-
$946.40 K(+1.7%)
$2.75 M(-19.5%)
Jun 2002
-
$930.40 K(+6.0%)
$3.42 M(-29.1%)
Mar 2002
-
$877.90 K(-45.6%)
$4.83 M(-12.9%)
Dec 2001
$3.97 M(-10.5%)
-
-
Sep 2001
-
$1.61 M(-30.9%)
$5.54 M(-3.8%)
Jun 2001
-
$2.34 M(+457.9%)
$5.76 M(+16.0%)
Mar 2001
-
$418.80 K(-64.3%)
$4.97 M(-15.2%)
Mar 2001
$4.44 M(-20.9%)
-
-
Dec 2000
-
$1.17 M(-36.0%)
$5.86 M(-0.5%)
Sep 2000
-
$1.83 M(+18.7%)
$5.89 M(+7.9%)
Jun 2000
-
$1.54 M(+17.7%)
$5.45 M(-1.0%)
Mar 2000
$5.61 M(+2.0%)
$1.31 M(+9.2%)
$5.51 M(-6.6%)
Dec 1999
-
$1.20 M(-14.3%)
$5.90 M(-4.8%)
Sep 1999
-
$1.40 M(-12.5%)
$6.20 M(+29.2%)
Jun 1999
-
$1.60 M(-5.9%)
$4.80 M(+50.0%)
Mar 1999
$5.50 M
$1.70 M(+13.3%)
$3.20 M(+113.3%)
Dec 1998
-
$1.50 M
$1.50 M

FAQ

  • What is Inovio Pharmaceuticals annual SGA?
  • What is the all time high annual SGA for Inovio Pharmaceuticals?
  • What is Inovio Pharmaceuticals annual SGA year-on-year change?
  • What is Inovio Pharmaceuticals quarterly SGA?
  • What is the all time high quarterly SGA for Inovio Pharmaceuticals?
  • What is Inovio Pharmaceuticals quarterly SGA year-on-year change?
  • What is Inovio Pharmaceuticals TTM SGA?
  • What is the all time high TTM SGA for Inovio Pharmaceuticals?
  • What is Inovio Pharmaceuticals TTM SGA year-on-year change?

What is Inovio Pharmaceuticals annual SGA?

The current annual SGA of INO is $47.58 M

What is the all time high annual SGA for Inovio Pharmaceuticals?

Inovio Pharmaceuticals all-time high annual SGA is $90.19 M

What is Inovio Pharmaceuticals annual SGA year-on-year change?

Over the past year, INO annual SGA has changed by -$42.60 M (-47.24%)

What is Inovio Pharmaceuticals quarterly SGA?

The current quarterly SGA of INO is $8.61 M

What is the all time high quarterly SGA for Inovio Pharmaceuticals?

Inovio Pharmaceuticals all-time high quarterly SGA is $48.46 M

What is Inovio Pharmaceuticals quarterly SGA year-on-year change?

Over the past year, INO quarterly SGA has changed by -$1.63 M (-15.91%)

What is Inovio Pharmaceuticals TTM SGA?

The current TTM SGA of INO is -$6.67 B

What is the all time high TTM SGA for Inovio Pharmaceuticals?

Inovio Pharmaceuticals all-time high TTM SGA is -$17.40 M

What is Inovio Pharmaceuticals TTM SGA year-on-year change?

Over the past year, INO TTM SGA has changed by -$6.72 B (-14123.99%)